LEVODOPA-INDUCED DIPHASIC DYSKINESIAS IMPROVED BY SUBCUTANEOUS APOMORPHINE

被引:14
作者
DESAINTVICTOR, JF
POLLAK, P
GERVASON, CL
PERRET, J
机构
[1] Department of Clinical and Biological Neurosciences, INSERM Preclinical Neurobiology U 318, Joseph Fourier University of Grenoble, Grenoble
关键词
D O I
10.1002/mds.870070316
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
[No abstract available]
引用
收藏
页码:283 / 284
页数:2
相关论文
共 10 条
[1]  
Tolosa ES, Martin WE, Cohen HP., Dyskinesias during levodopa therapy, Lancet, 1, pp. 1381-1382, (1975)
[2]  
Muenter MD, Sharpless NS, Tyce GM, Darley F., Patterns of dystonia (“I‐D‐I” and “D‐I‐D”) in response to l‐DOPA therapy for Parkinson's disease, Mayo Clin Proc, 52, pp. 163-174, (1977)
[3]  
Marsden CD, Parkes JD, Quinn N., Fluctuations of disability in Parkinson's disease: clinical aspects, Movement disorders, pp. 96-122, (1981)
[4]  
Poewe WH, Lees AJ, Stern GM., Dystonia in Parkinson's disease: clinical and pharmacological features, Ann Neurol, 23, pp. 73-78, (1988)
[5]  
Lhermitte F, Agid Y, Signoret JL., Onset and end of dose levodopa induced dyskinesia: possible treatment by increasing the daily doses of levodopa, Arch Neurol, 35, pp. 261-263, (1978)
[6]  
Duby SE, Cotzias GC, Papavasiliou PS, Lawrence WH., Injected apomorphine and orally administered levodopa in parkinsonism, Arch Neurol, 27, pp. 474-480, (1972)
[7]  
Agid Y, Bonnet AM, Signoret JL, Lhermitte F., Clinical, pharmacological, and biochemical approach of “onset‐ and end‐of dose” dyskinesias, The extrapyramidal system and its disorders, pp. 401-409, (1979)
[8]  
Fahn S., Fluctuations of disability in Parkinson's disease: Pathophysiology, Movement disorders, pp. 123-145, (1981)
[9]  
Gancher ST, Woodward WR, Boucher B, Nutt JG., Peripheral pharmacokinetics of apomorphine in humans, Ann Neurol, 26, pp. 232-238, (1989)
[10]  
Frankel JP, Lees A, Kempster PA, Stern GM., Subcutaneous apomorphine in the treatment of Parkinson's disease, J Neurol Neurosurg Psychiatry, 53, pp. 96-101, (1990)